Evaluation of drug-drug interaction screening software combined with pharmacist intervention

International Journal of Clinical Pharmacy

Volumn 34, Issue 4, 2012, Pages 547-552

  Moura, Cristiano S ^a   Prado, Nília M ^a   Belo, Najara O ^a   Acurcio, Francisco A ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Brazil; Drug drug interactions; Pharmacist intervention; Prescriptions; Screening software

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMIODARONE; CAPTOPRIL; CHLORPROMAZINE; DEXAMETHASONE; DIGOXIN; FENTANYL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; MOXIFLOXACIN; PANCURONIUM; PROPRANOLOL; RIFAMPICIN; SPIRONOLACTONE; WARFARIN;

ARTICLE; COMPUTER PROGRAM; DRUG COST; DRUG EFFICACY; DRUG INTERACTION; DRUG POTENTIATION; HOSPITAL PATIENT; HUMAN; PHARMACIST; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RISK REDUCTION;

ADULT; BRAZIL; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHARMACISTS; PROFESSIONAL ROLE; SOFTWARE;

EID: 84867403457     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9642-2     Document Type: Article

References (28)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192-9.
2. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20(6):626-34.
3. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991;266(20):2847-51.
4. Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61(9):675-81.
5. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266-72.
6. Radosevic N, Gantumur M, Vlahovic-Palcevski V. Potentially inappropriate prescribing to hospitalised patients. Pharmacoepidemiol Drug Saf. 2008;17(7):733-7.
7. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage. 2008;35(5):535-43.
8. Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006;12(5):383-9.
9. Chan A, Yap KY, Koh D, Low XH, Cheung YT. Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians. Pharmacoepidemiol Drug Saf. 2011;20(9):939-47.
10. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther. 2001; 69(4):260-5.
11. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash). 2001;41(2):200-4.
12. Taylor LK, Tamblyn R. Reasons for physician non-adherence to electronic drug alerts. Stud Health Technol Inform. 2004;107(Pt 2):1101-5.
13. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 2005;28(1):67-80.
14. Humphries TL, Carroll N, Chester EA, Magid D, Rocho B. Evaluation of an electronic critical drug interaction program coupled with active pharmacist intervention. Ann Pharmacother. 2007;41(12):1979-85.
15. Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med. 2009;169(8):757-63.
16. Moura CS, Ribeiro AQ, Starling SM. Avaliação de interações medicamentosas potenciais em prescrições médicas do Hospital das clínicas da Universidade Federal de Minas Gerais. Lat Am J Pharm. 2007;26(4):596-601.
17. Tatro D. Drug Interaction Facts 2008: Facts and Comparisons. St. Louis: Wolters Kluwer Health Inc; 2008. ISBN: 15 7 439274 3.
18. Tobi H, Faber A, van den Berg PB, Drane JW. de Jong-van den Berg LT. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf. 2007;16(4):405-11.
19. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
20. Morales Conejo M, Moreno Cuerda VJ, Abellan Martinez J, Rubio R. Serious adverse events derived from the drug interactions of antiretroviral therapy. Rev Clin Esp. 2008;208(11): 557-60.
21. Papadopoulos J, Smithburger PL. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med. 2010;38(6 Suppl):S126-35.
22. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med. 2003;163(21):2625-31.
23. Paterno MD, Maviglia SM, Gorman PN, Seger DL, Yoshida E, Seger AC, et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc. 2009;16(1): 40-6.
24. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582): 185-91.
25. White CM, Dunn A, Tsikouris J, Waberski W, Felton K, Freeman-Bosco L, et al. An assessment of the safety of short-term amiodarone therapy in cardiac surgical patients with fentanylisoflurane anesthesia. Anesth Analg. 1999;89(3):585-9.
26. Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin? J Gen Intern Med. 2004;19(8):879-86.
27. Schneitman-McIntire O, Farnen TA, Gordon N, Chan J, Toy WA. Medication misadventures resulting in emergency department visits at and HMO medical center. Am J Health Syst Pharm. 1996;53(12):1416-22.
28. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9): 1331-6.